HENAN LINGRUI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.3 CNY | +8.68% |
|
+7.75% | +47.87% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,621 | 4,809 | 8,920 | 7,358 | 9,649 | 14,268 | - |
| Enterprise Value (EV) 1 | 5,621 | 4,809 | 8,920 | 7,358 | 9,649 | 14,268 | 14,268 |
| P/E ratio | 19.3 x | 14.8 x | 24.8 x | 15.9 x | 17.1 x | 22.4 x | 19.2 x |
| Yield | - | - | - | 4.6% | 4.68% | 3.48% | 4.07% |
| Capitalization / Revenue | 2.61 x | - | 3.31 x | 2.45 x | 2.91 x | 3.6 x | 3.16 x |
| EV / Revenue | 2.61 x | - | 3.31 x | 2.45 x | 2.91 x | 3.6 x | 3.16 x |
| EV / EBITDA | - | - | 19.5 x | 12.4 x | 13.1 x | 19.9 x | 17.4 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | 3.94 x | 2.9 x | 3.48 x | 4.87 x | 4.49 x |
| Nbr of stocks (in thousands) | 567,809 | 567,809 | 564,553 | 564,253 | 563,938 | 563,934 | - |
| Reference price 2 | 9.900 | 8.470 | 15.80 | 13.04 | 17.11 | 25.30 | 25.30 |
| Announcement Date | 4/28/20 | 4/28/21 | 4/25/22 | 4/25/23 | 4/25/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,157 | - | 2,694 | 3,002 | 3,311 | 3,963 | 4,518 |
| EBITDA 1 | - | - | 457.7 | 594.3 | 737 | 716 | 820 |
| EBIT 1 | - | - | 435 | 517.1 | 656.3 | 724 | 842 |
| Operating Margin | - | - | 16.15% | 17.23% | 19.82% | 18.27% | 18.64% |
| Earnings before Tax (EBT) 1 | - | - | 413.4 | 517 | 653 | 721 | 839 |
| Net income 1 | - | 325.5 | 361.5 | 465.3 | 568.1 | 641 | 746 |
| Net margin | - | - | 13.42% | 15.5% | 17.16% | 16.17% | 16.51% |
| EPS 2 | 0.5120 | 0.5730 | 0.6380 | 0.8190 | 1.003 | 1.130 | 1.320 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | 0.6000 | 0.8000 | 0.8800 | 1.030 |
| Announcement Date | 4/28/20 | 4/28/21 | 4/25/22 | 4/25/23 | 4/25/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 15.9% | 19.3% | 21.3% | 21.8% | 23.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | 12.6% | 13.4% |
| Assets 1 | - | - | - | - | - | 5,087 | 5,584 |
| Book Value Per Share 2 | - | - | 4.010 | 4.500 | 4.920 | 5.200 | 5.630 |
| Cash Flow per Share 2 | - | - | 1.490 | 1.470 | 1.430 | 1.210 | 1.390 |
| Capex 1 | - | - | - | 14.8 | 11 | 80 | 81 |
| Capex / Sales | - | - | - | 0.49% | 0.33% | 2.02% | 1.79% |
| Announcement Date | 4/28/20 | 4/28/21 | 4/25/22 | 4/25/23 | 4/25/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
25.3
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +47.87% | 1.97B | |
| +35.04% | 5.92B | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| -7.89% | 1.68B | |
| +0.09% | 1.65B | |
| -12.97% | 1.53B | |
| +33.40% | 1.38B |
- Stock Market
- Equities
- 600285 Stock
- Financials Henan Lingrui Pharmaceutical Co., Ltd.
